blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1957538

EP1957538 - USES OF ANTI-CD40 ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.03.2014
Database last updated on 19.10.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For all designated states
XOMA Technology Ltd.
2910 Seventh Street
Berkeley CA 94701 / US
[2013/21]
Former [2009/09]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For all designated states
Xoma Technology Ltd.
2910 Seventh Street
Berkeley CA 94701 / US
Former [2008/34]For all designated states
Novartis Pharma AG
Lichtstrasse 35
4056 Basel / CH
For all designated states
Xoma Technology Ltd.
2910 Seventh Street
Berkeley CA 94701 / US
Inventor(s)01 / AUKERMAN, Sharon, Lea
Novartis Pharma AG
P.O. Box 8097
Emeryville, CA 94662-8097 / US
02 / LUQMAN, Mohammad
Novartis Vaccines and Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097 / US
 [2012/52]
Former [2012/42]01 / AUKERMAN, Sharon, Lea
Novartis Pharma A
P.O. Box 8097
Emeryville, CA 94662-8097 / US
02 / LUQMAN, Mohammad
Novartis Vaccines and Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097 / US
Former [2008/34]01 / AUKERMAN, Sharon, Lea
Novartis AG 4560 Horton Street
Emeryville, CA 94608 / US
02 / LUQMAN, Mohammad
Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097
Emeryville, CA 94662-8097 / US
Representative(s)Marshall, Cameron John, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2013/21]Marshall, Cameron John, et al
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Former [2009/51]Marshall, Cameron John, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Former [2008/34]Marshall, Cameron John, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date06836747.301.11.2006
[2008/34]
WO2006US42601
Priority number, dateUS20050732580P01.11.2005         Original published format: US 732580 P
[2008/34]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007053661
Date:10.05.2007
Language:EN
[2007/19]
Type: A2 Application without search report 
No.:EP1957538
Date:20.08.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 10.05.2007 takes the place of the publication of the European patent application.
[2008/34]
Type: B1 Patent specification 
No.:EP1957538
Date:22.05.2013
Language:EN
[2013/21]
Search report(s)International search report - published on:EP01.11.2007
ClassificationIPC:C07K16/28
[2008/34]
CPC:
C07K16/2878 (EP,US); C07K16/28 (KR); A61K39/00 (KR);
A61P1/04 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P21/04 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/10 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P7/00 (EP); C07K16/2887 (EP,US); C07K2317/732 (EP,US);
C07K2317/77 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/34]
Extension statesAL30.05.2008
BA30.05.2008
HR30.05.2008
MK30.05.2008
RS30.05.2008
TitleGerman:ANWENDUNG VON ANTI-CD40-ANTIKÖRPERN[2008/34]
English:USES OF ANTI-CD40 ANTIBODIES[2008/34]
French:UTILISATIONS D'ANTICORPS ANTI-CD40[2008/34]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase30.05.2008National basic fee paid 
30.05.2008Designation fee(s) paid 
30.05.2008Examination fee paid 
Examination procedure30.05.2008Amendment by applicant (claims and/or description)
30.05.2008Examination requested  [2008/34]
29.06.2009Despatch of a communication from the examining division (Time limit: M06)
06.01.2010Reply to a communication from the examining division
23.02.2010Despatch of a communication from the examining division (Time limit: M06)
01.09.2010Reply to a communication from the examining division
26.11.2010Despatch of a communication from the examining division (Time limit: M06)
18.04.2011Reply to a communication from the examining division
16.05.2011Despatch of a communication from the examining division (Time limit: M04)
08.09.2011Reply to a communication from the examining division
10.10.2011Despatch of a communication from the examining division (Time limit: M04)
17.02.2012Reply to a communication from the examining division
02.05.2012Communication of intention to grant the patent
10.09.2012Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.11.2012Communication of intention to grant the patent
08.04.2013Fee for grant paid
08.04.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.06.2009
Opposition(s)25.02.2014No opposition filed within time limit [2014/18]
Fees paidRenewal fee
30.05.2008Renewal fee patent year 03
12.11.2009Renewal fee patent year 04
12.11.2010Renewal fee patent year 05
14.11.2011Renewal fee patent year 06
13.11.2012Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.11.2006
AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
IE01.11.2013
LU01.11.2013
CH30.11.2013
LI30.11.2013
[2015/34]
Former [2015/32]AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
IE01.11.2013
CH30.11.2013
LI30.11.2013
Former [2015/30]AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
IE01.11.2013
CH30.11.2013
LI30.11.2013
Former [2014/48]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
IE01.11.2013
CH30.11.2013
LI30.11.2013
Former [2014/34]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
CH30.11.2013
LI30.11.2013
Former [2014/33]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/14]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/11]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/10]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/09]AT22.05.2013
BE22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/06]AT22.05.2013
BE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/02]AT22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2013/50]AT22.05.2013
FI22.05.2013
LT22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2013/49]AT22.05.2013
FI22.05.2013
LT22.05.2013
SE22.05.2013
SI22.05.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2013/48]AT22.05.2013
LT22.05.2013
IS22.09.2013
PT23.09.2013
Former [2013/47]LT22.05.2013
PT23.09.2013
Cited inInternational search[A]WO03035904  (CHRU TOURS [FR], et al) [A] 1-20,24-38,47-53* claims 1-19 *;
 [A]  - LAW C-L ET AL, "Preclinical antitumor activity of a humanized anti-CD40 monoclonal antibody SGN-40", BIOSIS, (20050915), XP002310999 [A] 1-20,24-38,47-53 * abstract * * page 8337, column R, lines 7-17 *
 [A]  - LONG LI ET AL, "Antagonist anti-CD40 monoclonal antibody, CHIR-12.12, inhibits growth of a rituximab-resistant NHL xenograft model and achieves synergistic activity when combined with ineffective rituximab", BIOSIS, (20041116), XP002427479 [A] 1-20,24-38,47-53 * the whole document *
 [A]  - TAI YU-TZU ET AL, "Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (200507), vol. 65, no. 13, ISSN 0008-5472, pages 5898 - 5906, XP002427470 [A] 1-20,24-38,47-53 * abstract *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-04-4125
 [AD]  - DALL'OZZO SEBASTIEN ET AL, "Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship", CANCER RESEARCH, (20040701), vol. 64, no. 13, ISSN 0008-5472, pages 4664 - 4669, XP002433841 [AD] 1-20,24-38,47-53 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-03-2862
 [A]  - CARTRON G ET AL, "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, (20020201), vol. 99, no. 3, ISSN 0006-4971, pages 754 - 758, XP002404674 [A] 1-20,24-38,47-53 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood.V99.3.754
 [A]  - SIBILIA J ET AL, "IMMUNOTHERAPY OF INFLAMMATORY DISEASES, 2005", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, (200509), vol. 5, no. SUPPL 1, ISSN 1471-2598, pages S01 - S13, XP009060332 [A] 1-20,24-38,47-53 * page S4, column L *

DOI:   http://dx.doi.org/10.1517/14712598.5.1.S1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.